The Secretary of State for Health

Micropharm Limited

Helen Ahern

Clifford Charles Shone

John Landon

April Roberts

Michael Maynard-Smith

Clifford Shone

The present invention relates to recombinantantigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of aToxin A sequence or residues 1500-1851 of aToxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of aToxin A sequence or within amino acid residues 1852-2366 of aToxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of aToxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of aToxin B. Also provided is the use of said antigens for the prevention/treatment/suppression ofinfection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

Growing community of inventors

Salisbury, United Kingdom

Helen Ahern